Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The aim of this study was to evaluate the effectiveness of treatment with methylphenidate or desmopressin (dDAVP) in patients with comorbid attention-deficit/hyperactivity disorder (ADHD) and enuresis.

Methods: We enrolled 103 patients affected by ADHD and 125 patients with monosymptomatic nocturnal enuresis (NE). Data were collected between January 2014 and December 2015. The study was carried out in compliance with the Helsinki Declaration.

Results: About children with ADHD, 9/103 (8.7%) were also suffering from NE; of those 8/9 followed treatment with methylphenidate and cognitive behavioral therapy. After 3 months 2/8 (25%, CI 95%: 8-65%) showed improvements, remaining 75% has been increased dosage of methylphenidate. After 6 months a response was achieved in 6/8 (75%, CI 95%: 35-96%) children and 1/8 was lost to follow-up. Furthermore the drug withdrawal showed a recurrence of symptoms both ADHD and NE in 1/7 (14.3%, CI 95%: 0.3-57%) vs. 6/7 (85.7%, CI 95%: 42-99%) that not presented recurrences. About children with NE enrolled at Campus Bio-Medico University it was found that 4/125 (3.8%) children were also suffering from ADHD; 3/4 (75%) treated with dDAVP and motivational therapy, of those 2/3 (66.7%, CI 95%: 9-99%) showed no improvements of symptoms vs. 1/3 (33.3%, CI 95%: 0.8-90%) that showed partial response with a reduction of wet-nights.

Conclusions: It is important the service of recruitment of patients with NE. In fact considering NE in a Child Neuropsychiatry Service where patients belong to a diagnosis of ADHD and NE is an incidental finding, this one is not considered as the addressee of treatment, but the therapy is directed to the neuro-behavioral problem using specific drugs and therapies, which are resolutive in the enuretic disorder.

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0026-4946.17.04680-1DOI Listing

Publication Analysis

Top Keywords

treatment methylphenidate
12
attention-deficit/hyperactivity disorder
8
effectiveness treatment
8
methylphenidate desmopressin
8
adhd
6
95%
6
patients
5
disorder enuresis
4
enuresis study
4
study effectiveness
4

Similar Publications

Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies.

J Psychiatr Res

September 2025

Genomics and Bioinformatics Group, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Genetics Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain; Fund

Methylphenidate (MPH) is the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a condition that disrupts daily functioning. Research indicates that individuals with ADHD often experience sensory processing impairments, regardless of co-occurring conditions. Given the growing interest in pharmacogenetics to personalise treatments and minimise side effects, this study aims to characterise the sensory profiles of in child and youth ADHD patients treated with MPH and investigate potential pharmacogenetic biomarkers that could be associated with treatment outcomes or sensory-related side effects.

View Article and Find Full Text PDF

Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice.

View Article and Find Full Text PDF

Objective: Methylphenidate is effective in reducing ADHD symptoms in the short term, but long-term benefits are inconsistent, possibly due to the development of tolerance. Moreover, little is known about its sustained effects on brain functional connectivity. We examined whether a 4-month methylphenidate treatment leads to sustained alterations in resting-state functional connectivity, and whether acute brain responses to methylphenidate decrease after treatment, as a potential marker of neurobiological tolerance.

View Article and Find Full Text PDF

Objectives: This study aimed to evaluate and compare the effects of methylphenidate on oral health, salivary flow rate, and quality of life in children with Attention-Deficit/Hyperactivity Disorder (ADHD), focusing on differences between short-release methylphenidate (SRM) and long-release methylphenidate (LRM) formulations.

Materials And Methods: A total of 99 children participated in this cross-sectional study (ADHD: n = 49; divided into SRM (n = 27) and LRM (n = 22) subgroups based on medication type; control: n = 50). Dental caries was assessed using the DMFT/dft indices and the International Caries Detection and Assessment System (ICDAS), while oral hygiene was evaluated using the Plaque Index (PI), Gingival Index (GI), and Bleeding on Probing (BOP).

View Article and Find Full Text PDF

Characterization of mice with cell type-specific Gnal loss of function provides insights on GNAL-linked dystonia.

Neurobiol Dis

September 2025

Inserm UMR-S 1270, Paris 75005, France; Sorbonne Université, Faculty of Sciences and Engineering, Paris 75005, France; Institut du Fer à Moulin, 17 rue du Fer à Moulin, Paris 75005, France; Sorbonne Université, Institut du Cerveau, Inserm, CNRS, AP-HP, Institut de Neurologie, Hôpital de la Salp

Isolated dystonia can be caused by loss-of-function mutations in the GNAL gene (DYT-GNAL/DYT25). This gene encodes the α subunit of the heterotrimeric G protein, which, with βγ subunits, mediates the stimulatory coupling of dopamine D1 and adenosine A2A receptors to adenylyl-cyclase. These receptors are expressed in distinct striatal projection neurons (SPNs) with complementary functions in motor behavior.

View Article and Find Full Text PDF